Trial Profile
A phase 1 trial is to evaluate the safety, tolerability, and pharmacokinetics of the oral formulation of CC8464 for the treatment of pain
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2017
Price :
$35
*
At a glance
- Drugs CC 8464 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 27 Jun 2017 According to a Chromocell Corporation media release, the company received an additional milestone payment from Astellas Pharmaceuticals Inc. for the initiation of the multiple ascending dose portion of this trial.
- 06 Oct 2015 New trial record
- 30 Sep 2015 According to an Astellas Pharma media release, Chromocell anticipates filing an IND for CC8464 in early 2016.